Title
Robotic Surgery for Rectal Cancer Provides Advantageous Outcomes Over Laparoscopic Approach: Results From a Large Retrospective Cohort.
Type
journal article
Institution
UNIL/CHUV/Unisanté + partner institutions
Journal
Author(s)
Crippa, J.
Author
Grass, F.
Author
Dozois, E.J.
Author
Mathis, K.L.
Author
Merchea, A.
Author
Colibaseanu, D.T.
Author
Kelley, S.R.
Author
Larson, D.W.
Author
Links to people
Links to units
ISSN
1528-1140
Editorial status
Published
Date Issued
2021-12-01
Volume
274
Issue
6
First page
e1218
Last page/article number
e1222
Peer-reviewed
True
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To compare short term outcomes of patients undergoing laparoscopic or robotic rectal cancer surgery.
Significant benefits of robotic rectal cancer surgery over laparoscopy have yet to be demonstrated. Operative time and direct institutional cost seem in favor of the laparoscopic approach.
We performed a retrospective review of consecutive patients operated on for rectal cancer with a mini-invasive approach at Mayo Clinic from 2005 to 2018. The primary aim of this study was to investigate the difference in postoperative morbidity between the laparoscopic and robotic approach. Multivariable models for odds to complications and prolonged (≥6 days) length of stay were built.
A total of 600 patients were included in the analysis. The number of patients undergoing robotic surgery was 317 (52.8%). The 2 groups were similar in respect to age, sex, and body mass index. Laparoscopic surgery was correlated to shorter operative time (214 vs 324 minutes; P < 0.001). Patients undergoing robotic surgery had a lower overall complications rate (37.2% vs 51.2%; P < 0.001). Robotic surgery was found to be the most protective factor [odds ratio (OR) 0.485; P = 0.006] for odds to complications. The event of a complication (OR 9.33; P < 0.001) and conversion to open surgery (OR 3.095; P = 0.002) were identified as risk factors for prolonged length of stay whereas robotic surgery (OR 0.62; P = 0.027) was the only independent protective factor.
Robotic rectal cancer surgery is strongly associated with better short-term outcomes over laparoscopic surgery.
Significant benefits of robotic rectal cancer surgery over laparoscopy have yet to be demonstrated. Operative time and direct institutional cost seem in favor of the laparoscopic approach.
We performed a retrospective review of consecutive patients operated on for rectal cancer with a mini-invasive approach at Mayo Clinic from 2005 to 2018. The primary aim of this study was to investigate the difference in postoperative morbidity between the laparoscopic and robotic approach. Multivariable models for odds to complications and prolonged (≥6 days) length of stay were built.
A total of 600 patients were included in the analysis. The number of patients undergoing robotic surgery was 317 (52.8%). The 2 groups were similar in respect to age, sex, and body mass index. Laparoscopic surgery was correlated to shorter operative time (214 vs 324 minutes; P < 0.001). Patients undergoing robotic surgery had a lower overall complications rate (37.2% vs 51.2%; P < 0.001). Robotic surgery was found to be the most protective factor [odds ratio (OR) 0.485; P = 0.006] for odds to complications. The event of a complication (OR 9.33; P < 0.001) and conversion to open surgery (OR 3.095; P = 0.002) were identified as risk factors for prolonged length of stay whereas robotic surgery (OR 0.62; P = 0.027) was the only independent protective factor.
Robotic rectal cancer surgery is strongly associated with better short-term outcomes over laparoscopic surgery.
Serval PID
serval:BIB_BCF2DCA01391
PMID
Creation date
2021-11-29T09:31:48.801Z
Creation date in IRIS
2025-05-21T01:55:23Z
File(s)![Thumbnail Image]()
Loading...
Name
Robotic_Surgery_for_Rectal_Cancer_Provides.423.pdf
Manuscript version
published
Visibility
Open Access
Size
143.8 KB
Format
Adobe PDF
Serval PID
serval:BIB_BCF2DCA01391.P001
Checksum
(MD5):230cd64c22012cfe039d567d37821fda